알부민 시장 규모 : 제품별, 용도별, 최종사용자별, 세계 예측(2024-2032년)

Global Albumin Market size will register a 6.5% CAGR from 2024 to 2032 due to the growing biotechnology sector and increasing use in diagnostic applications. In biotechnology, albumin is crucial for cell culture and protein expression, fueling its demand. Additionally, albumin serves as a vital biomarker in diagnostic tests for liver and kidney disorders, contributing to its market growth. With the rising prevalence of chronic diseases and the need for accurate diagnostic tools, the albumin industry will expand, offering essential solutions for biotechnology and diagnostic applications.

For instance, in August 2023, Dyadic reported further advancements in the commercialization of animal-free recombinant serum albumin, demonstrating significant progress toward its goal.

The albumin industry is classified based on product, application, drug and device formulation, end-user, and region.

The diagnostic application segment will capture a remarkable share by 2032. Albumin's role as a biomarker for various diseases, including liver and kidney disorders, drives its demand in diagnostic tests. It is used to assess protein status and renal function, aiding in the early detection and monitoring of diseases. With the increasing prevalence of chronic conditions worldwide, the diagnostic application segment will experience substantial growth, offering essential tools for healthcare professionals in disease diagnosis and management.

The albumin market share from the pharmaceutical and biotechnology industry segment will achieve notable gains through 2032, attributed to albumin's extensive use in drug formulation, cell culture, and vaccine production. Pharmaceutical companies utilize albumin as a stabilizer and carrier for various drugs. In biotechnology, albumin plays a crucial role in cell culture media for protein expression. With the increasing demand for biopharmaceuticals and vaccines, the pharmaceutical and biotechnology industry segment will drive significant expansion in the market.

Asia Pacific albumin industry will exhibit a noteworthy CAGR by 2032, driven by factors such as the rising prevalence of chronic diseases, increasing demand for albumin in medical treatments, and a growing aging population. Albumin's vital role in therapies like fluid replacement and liver disease treatment further boosts its demand. With a burgeoning healthcare sector and substantial investments in research and development, Asia Pacific will stand as a key contributor to the albumin market growth and expansion, catering to the region's healthcare needs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Growing non-therapeutic application of albumin
    • 3.2.1.3 Increase in demand for albumin in R&D activities
    • 3.2.1.4 Technological advancements in biotechnology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Irrational uses and adverse effects associated with albumin
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Human serum albumin
• 5.3 Bovine serum albumin
• 5.4 Recombinant albumin

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical applications
  • 6.2.1 Drug delivery
  • 6.2.2 Emergency treatment of shock
  • 6.2.3 Burn treatment
  • 6.2.4 Intravenous therapy
  • 6.2.5 Other clinical applications
• 6.3 Drug and device formulation
  • 6.3.1 Drug formulation
  • 6.3.2 Cell culture media ingredients
  • 6.3.3 Vaccine ingredients/stabilization
  • 6.3.4 Other drug and device formulation applications
• 6.4 Diagnostic applications
• 6.5 Gene therapy formulation
• 6.6 Nutritional supplements
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Pharmaceutical & biotechnology industry
• 7.4 Research institutes and laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Albumedix Ltd
• 9.2 Akron Biotech
• 9.3 Baxter International Inc.
• 9.4 Bristol-Myers Squibb Company
• 9.5 China Biologic Products Holdings Inc.
• 9.6 CSL Behring LLC
• 9.7 Grifols (Biotest AG)
• 9.8 Merck & Co., Inc.
• 9.9 Octapharma AG
• 9.10 Thermo Fisher Scientific Inc.